Safety of etanercept with contrast ultrasound for Alzheimer's
Part of Brain & nervous system, Mental health clinical trials.
This study tests whether combining a drug called etanercept with repeated contrast ultrasound is safe for people with mild Alzheimer's. It aims to see if this approach can help slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of Alzheimer's disease (mild stage).
- You are between 50 and 85 years old.
- You have not been treated with etanercept or similar drugs before.
- You are not taking blood thinners or have certain heart or lung conditions.
- You can have an MRI and a lumbar puncture (spinal tap).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a non-surgical ultrasound procedure (called MR-guided focused ultrasound) meant to temporarily “open” the brain’s protective barrier so treatments may work better for Alzheimer’s disease. It also looks at safety and how well people tolerate the procedure and related tests.
This study tests a new treatment using focused ultrasound to temporarily open the barrier between your blood and brain. This may allow natural waste-clearing cells to work better and help slow the progression of Alzheimer's symptoms.
This study tests an experimental drug (LY3954068) for people with early Alzheimer's disease. It aims to see if the drug is safe and may slow memory loss. You'll need a PET scan to measure tau protein in the brain and have a study partner who can help attend appointments.
This study tests antibody treatments that target amyloid plaques in the brain for people with mild memory or thinking problems. It may help determine if you are a candidate for these new drugs and monitors your safety through regular scans and checkups.
This study looks at how effective a treatment is in people newly diagnosed with mild to moderate Alzheimer’s disease. It also involves health and medication history checks and likely stool (fecal) sample collection to monitor effects.
This trial tests an investigational drug called AMDX-2011P for people with Alzheimer's disease. It looks at whether the drug affects the retina, which may be linked to brain changes in Alzheimer's.
Hear when a new Alzheimer Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.